Back

Incidence, predictors and outcomes of non-home discharge following transcatheter aortic valve implantation: a multicentre Australian experience. The NHD TAVI study.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Advancing knowledge in valvular heart disease: the role of registries Aortic Valve Stenosis ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Anant Butala

The Alfred Hospital, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
Overview of the risk of myocardial infarction in patients with aortic stenosis: insights from the VALVENOR Registry.
Professor G. Lemesle (Lille, FR)
Abstract Slides Video
Presentation thumbnail
Gender-specific differences in severe tricuspid regurgitation. Finding from a TR multicentre CMR registry
Doctor S. Rodriguez Diego (Salamanca, ES)
Abstract Slides Video
Presentation thumbnail
Effect of severe tricuspid regurgitation on the prognosis of patients with atrial functional mitral regurgitation: the REVEAL-AFMR registry
Doctor T. Kaneko (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Natural progression of rheumatic aortic valve disease following rheumatic mitral valve intervention: 16-year single center experience
Assistant Professor S. Kim (Yangsan, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing knowledge in valvular heart disease: the role of registries

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Safe transition home after transcatheter aortic valve implantation feasibility (START-F) study: Very early self-reported function and recovery status after early discharge
thumbnail
Congress Presentation
Implementing a novel selection criteria and pathway for same-day discharge after TAVI
thumbnail
Congress Presentation
Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources